Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.

J Urol. 2019 Jan;201(1):91-97. doi: 10.1016/j.juro.2018.08.043.

PMID:
30577397
2.

Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.

Mertan FV, Greer MD, Shih JH, George AK, Kongnyuy M, Muthigi A, Merino MJ, Wood BJ, Pinto PA, Choyke PL, Turkbey B.

J Urol. 2016 Sep;196(3):690-6. doi: 10.1016/j.juro.2016.04.057. Epub 2016 Apr 18.

PMID:
27101772
3.

Prediction of biochemical recurrence after radical prostatectomy with PI-RADS version 2 in prostate cancers: initial results.

Park SY, Oh YT, Jung DC, Cho NH, Choi YD, Rha KH, Hong SJ.

Eur Radiol. 2016 Aug;26(8):2502-9. doi: 10.1007/s00330-015-4077-5. Epub 2015 Nov 11.

PMID:
26560721
4.

Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.

Sheridan AD, Nath SK, Syed JS, Aneja S, Sprenkle PC, Weinreb JC, Spektor M.

AJR Am J Roentgenol. 2018 Feb;210(2):347-357. doi: 10.2214/AJR.17.18516. Epub 2017 Nov 7.

PMID:
29112469
5.

Biparametric Prostate Imaging Reporting and Data System version2 and International Society of Urological Pathology Grade Predict Biochemical Recurrence after Radical Prostatectomy.

Takeuchi N, Sakamoto S, Nishiyama A, Horikoshi T, Yamada Y, Iizuka J, Maimaiti M, Imamura Y, Kawamura K, Imamoto T, Komiya A, Ikehara Y, Akakura K, Ichikawa T.

Clin Genitourin Cancer. 2018 Aug;16(4):e817-e829. doi: 10.1016/j.clgc.2018.02.011. Epub 2018 Feb 24.

PMID:
29576444
6.

Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.

Radtke JP, Kuru TH, Boxler S, Alt CD, Popeneciu IV, Huettenbrink C, Klein T, Steinemann S, Bergstraesser C, Roethke M, Roth W, Schlemmer HP, Hohenfellner M, Hadaschik BA.

J Urol. 2015 Jan;193(1):87-94. doi: 10.1016/j.juro.2014.07.098. Epub 2014 Jul 28.

PMID:
25079939
7.

Multicentre evaluation of targeted and systematic biopsies using magnetic resonance and ultrasound image-fusion guided transperineal prostate biopsy in patients with a previous negative biopsy.

Hansen NL, Kesch C, Barrett T, Koo B, Radtke JP, Bonekamp D, Schlemmer HP, Warren AY, Wieczorek K, Hohenfellner M, Kastner C, Hadaschik B.

BJU Int. 2017 Nov;120(5):631-638. doi: 10.1111/bju.13711. Epub 2016 Dec 21.

8.

PI-RADSv2 Category on 3 Tesla Multiparametric Prostate MRI Predicts Oncologic Outcomes in Gleason 3+4 Prostate Cancer on Biopsy.

Faiena I, Salmasi A, Mendhiratta N, Markovic D, Ahuja P, Hsu W, Elashoff DA, Raman SS, Reiter RE.

J Urol. 2018 Aug 21. pii: S0022-5347(18)43729-9. doi: 10.1016/j.juro.2018.08.043. [Epub ahead of print]

PMID:
30142318
9.

Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol.

Luzzago S, Musi G, Catellani M, Russo A, Di Trapani E, Mistretta FA, Bianchi R, Cozzi G, Conti A, Pricolo P, Ferro M, Matei DV, Mirone V, Petralia G, de Cobelli O.

Urol Int. 2018;101(1):56-64. doi: 10.1159/000488772. Epub 2018 May 7.

PMID:
29734177
10.

Pre-biopsy 3-Tesla MRI and targeted biopsy of the index prostate cancer: correlation with robot-assisted radical prostatectomy.

Patel U, Dasgupta P, Challacombe B, Cahill D, Brown C, Patel R, Kirby R.

BJU Int. 2017 Jan;119(1):82-90. doi: 10.1111/bju.13525. Epub 2016 Jun 3.

11.

Risk-stratification based on magnetic resonance imaging and prostate-specific antigen density may reduce unnecessary follow-up biopsy procedures in men on active surveillance for low-risk prostate cancer.

Alberts AR, Roobol MJ, Drost FH, van Leenders GJ, Bokhorst LP, Bangma CH, Schoots IG.

BJU Int. 2017 Oct;120(4):511-519. doi: 10.1111/bju.13836. Epub 2017 Apr 4.

12.

Multiparametric magnetic resonance imaging guided diagnostic biopsy detects significant prostate cancer and could reduce unnecessary biopsies and over detection: a prospective study.

Thompson JE, Moses D, Shnier R, Brenner P, Delprado W, Ponsky L, Pulbrook M, Böhm M, Haynes AM, Hayen A, Stricker PD.

J Urol. 2014 Jul;192(1):67-74. doi: 10.1016/j.juro.2014.01.014. Epub 2014 Feb 8.

PMID:
24518762
13.

Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.

Song W, Bang SH, Jeon HG, Jeong BC, Seo SI, Jeon SS, Choi HY, Kim CK, Lee HM.

Clin Genitourin Cancer. 2018 Aug;16(4):281-287. doi: 10.1016/j.clgc.2018.02.015. Epub 2018 Feb 23.

PMID:
29550198
15.

Lesion volume predicts prostate cancer risk and aggressiveness: validation of its value alone and matched with prostate imaging reporting and data system score.

Martorana E, Pirola GM, Scialpi M, Micali S, Iseppi A, Bonetti LR, Kaleci S, Torricelli P, Bianchi G.

BJU Int. 2017 Jul;120(1):92-103. doi: 10.1111/bju.13649. Epub 2016 Oct 4.

16.

Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?

Xu N, Wu YP, Chen DN, Ke ZB, Cai H, Wei Y, Zheng QS, Huang JB, Li XD, Xue XY.

J Cancer Res Clin Oncol. 2018 May;144(5):987-995. doi: 10.1007/s00432-018-2616-6. Epub 2018 Mar 5.

PMID:
29504080
17.

PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer.

Woo S, Kim SY, Lee J, Kim SH, Cho JY.

Eur Radiol. 2016 Oct;26(10):3580-7. doi: 10.1007/s00330-016-4230-9. Epub 2016 Feb 4.

PMID:
26847042
18.

Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?

Lanz C, Cornud F, Beuvon F, Lefèvre A, Legmann P, Zerbib M, Delongchamps NB.

J Urol. 2016 Jan;195(1):88-93. doi: 10.1016/j.juro.2015.07.021. Epub 2015 Jul 10.

PMID:
26165586
19.

Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.

Radtke JP, Wiesenfarth M, Kesch C, Freitag MT, Alt CD, Celik K, Distler F, Roth W, Wieczorek K, Stock C, Duensing S, Roethke MC, Teber D, Schlemmer HP, Hohenfellner M, Bonekamp D, Hadaschik BA.

Eur Urol. 2017 Dec;72(6):888-896. doi: 10.1016/j.eururo.2017.03.039. Epub 2017 Apr 8.

PMID:
28400169

Supplemental Content

Support Center